Abstract
HIV-1 Tat protein has been shown to have a crucial role in HIV-1-associated neurocognitive disorders (HAND), which includes a group of syndromes ranging from undetectable neurocognitive impairment to dementia. The abuse of psychostimulants, such as cocaine, by HIV infected individuals, may accelerate and intensify neurological damage. On the other hand, exposure to Tat potentiates cocaine-mediated reward mechanisms, which further promotes HAND. Here, we show that didehydro-Cortistatin A (dCA), an analog of a natural steroidal alkaloid, crosses the blood-brain barrier, cross-neutralizes Tat activity from several HIV-1 clades and decreases Tat uptake by glial cell lines. In addition, dCA potently inhibits Tat mediated dysregulation of IL-1β, TNF-α and MCP-1, key neuroinflammatory signaling proteins. Importantly, using a mouse model where doxycycline induces Tat expression, we demonstrate that dCA reverses the potentiation of cocaine-mediated reward. Our results suggest that adding a Tat inhibitor, such as dCA, to current antiretroviral therapy may reduce HIV-1-related neuropathogenesis.
Keywords: Cocaine, conditioned place preference, didehydro-Cortistatin A, HAND, HIV-1, neuroinflammation, reward, Tat.
Current HIV Research
Title:Didehydro-Cortistatin A Inhibits HIV-1 Tat Mediated Neuroinflammation and Prevents Potentiation of Cocaine Reward in Tat Transgenic Mice
Volume: 13 Issue: 1
Author(s): Sonia Mediouni, Joseph Jablonski, Jason J. Paris, Mark A. Clementz, Suzie Thenin-Houssier, Jay P. McLaughlin and Susana T. Valente
Affiliation:
Keywords: Cocaine, conditioned place preference, didehydro-Cortistatin A, HAND, HIV-1, neuroinflammation, reward, Tat.
Abstract: HIV-1 Tat protein has been shown to have a crucial role in HIV-1-associated neurocognitive disorders (HAND), which includes a group of syndromes ranging from undetectable neurocognitive impairment to dementia. The abuse of psychostimulants, such as cocaine, by HIV infected individuals, may accelerate and intensify neurological damage. On the other hand, exposure to Tat potentiates cocaine-mediated reward mechanisms, which further promotes HAND. Here, we show that didehydro-Cortistatin A (dCA), an analog of a natural steroidal alkaloid, crosses the blood-brain barrier, cross-neutralizes Tat activity from several HIV-1 clades and decreases Tat uptake by glial cell lines. In addition, dCA potently inhibits Tat mediated dysregulation of IL-1β, TNF-α and MCP-1, key neuroinflammatory signaling proteins. Importantly, using a mouse model where doxycycline induces Tat expression, we demonstrate that dCA reverses the potentiation of cocaine-mediated reward. Our results suggest that adding a Tat inhibitor, such as dCA, to current antiretroviral therapy may reduce HIV-1-related neuropathogenesis.
Export Options
About this article
Cite this article as:
Mediouni Sonia, Jablonski Joseph, Paris J. Jason, Clementz A. Mark, Thenin-Houssier Suzie, McLaughlin P. Jay and Valente T. Susana, Didehydro-Cortistatin A Inhibits HIV-1 Tat Mediated Neuroinflammation and Prevents Potentiation of Cocaine Reward in Tat Transgenic Mice, Current HIV Research 2015; 13 (1) . https://dx.doi.org/10.2174/1570162X13666150121111548
DOI https://dx.doi.org/10.2174/1570162X13666150121111548 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Vitro and In Vivo Metabolism of a Gamma-Secretase Inhibitor BMS-299897 and Generation of Active Metabolites in Milligram Quantities with a Microbial Bioreactor
Current Drug Metabolism Identification of New Chromenone Derivatives as Cholinesterase Inhibitors and Molecular Docking Studies
Medicinal Chemistry Current Strategies and Novel Drug Approaches for Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Current Medicinal Chemistry Something Old, Something New and Something Used in Alzheimer's; the Idea of Pore, Ethanol and the Use of Oocytes to Understand the Disease
Current Chemical Biology Crocin Protects Against Beta-Amyloid Peptide-Induced Apoptosis in PC12 Cells Via the PI3 K Pathway
Current Molecular Pharmacology Sleep, Depression and Insomnia – A Vicious Circle?
Current Psychiatry Reviews Reduced Risk of Incident AD with Elective Statin Use in a Clinical Trial Cohort
Current Alzheimer Research Spin Trapping: An Essential Tool for the Study of Diseases Caused by Oxidative Stress
Current Topics in Medicinal Chemistry Optimized Turmeric Extracts have Potent Anti-Amyloidogenic Effects
Current Alzheimer Research Cardiovascular Complications in Patients with Klinefelter’s Syndrome
Current Pharmaceutical Design Editorial [Hot Topic: Exploring the Links between Obesity and Alzheimers Disease (Guest Editor: Suzana S. Petanceska) ]
Current Alzheimer Research A Study of Tryptophan Metabolism via Serotonin in Ventricular Cerebrospinal Fluid in HIV-1 Infection Using a Neuroendoscopic Technique
Current HIV Research Clinically Relevant Pharmacokinetic Herb-drug Interactions in Antiretroviral Therapy
Current Drug Metabolism Pharmacological Intervention at Ionotropic Glutamate Receptor Complexes
Current Pharmaceutical Design Can Apolipoproteins and Complement Factors be Biomarkers of Alzheimer’s Disease?
Current Alzheimer Research Bioactive Compounds in Some Culinary Aromatic Herbs and Their Effects on Human Health
Mini-Reviews in Medicinal Chemistry Mitochondrial-Associated Metabolic Changes and Neurodegeneration in Huntingtons Disease - from Clinical Features to the Bench
Current Drug Targets Exogenous Progesterone: A Potential Therapeutic Candidate in CNS Injury and Neurodegeneration
Current Medicinal Chemistry Enhanced Risk for Specific Somatic Myeloproliferative Neoplastic Mutations in Patients with Stroke
Current Neurovascular Research